Organisation paid for research Program year 2025 Source: CMS Open Payments

InComm Digital Solutions, LLC

Neither a doctor nor a teaching hospital

Research payments

$611,976

233 payments

Through program year 2025, InComm Digital Solutions, LLC is reported as receiving $611,976 in research payments, across 233 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$949	5
2024	Research	$261,348	99
2023	Research	$349,679	129

Breakdown

Who paid Research payments · program years 2023–2025

Glaukos Corporation $611,976 233 payments

Studies the money was for Research payments · program years 2023–2025

A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $115,576 48 payments
A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus $87,200 28 payments
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $58,982 23 payments
A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus $29,478 4 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $21,930 6 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $19,584 5 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $13,260 3 payments
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus $12,240 3 payments
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $11,447 4 payments
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $10,677 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.